NewsScienceAbout Contact

News

Advancing siRNA Drug Discovery and Development with AI

Pheiron and Ribo have successfully achieved their first two milestones, advancing AI-assisted drug discovery and development for siRNA therapeutics.

May 2, 2025

5

min read

Pheiron @BIO-Europe Spring 2025

Pheiron will be attending the 19th annual BIO-Europe Spring conference taking place March 17-19, 2025 in Milan, Italy. The event will bring together over 3,700 leading executives from around the world to engage in over 20,000 partnering meetings, connecting leaders from academia, start-up, and scale-up biotech companies with forward-thinking investors and pharma companies.

March 13, 2025

5

min read

Pheiron enters strategic collaboration with Ribocure

This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology.

September 24, 2024

3

min read

Using an ECG-based
AI-Biomarker to assess GLP-1’s Real-World Cardioprotective Benefits

At Pheiron, we use AI to integrate multi-omic data and accurately capture disease pathophysiology accurately in AI-driven biomarkers. One key application of our AI-biomarkers is in enhancing the evidence generated from RCTs and real-world observational studies. Here we validated and applied one of our AI-biomarkers, an algorithm predicting cardiovascular risk from 12-lead ECGs in collaboration with DandelionHealth.

September 18, 2024

5

min read

The GPS for drug development: navigating with evidence from human populations

Stakeholders lack critical evidence on whether their drug target will work in humans before trialing for it, and they lack tools to use insights on target biology to optimize clinical positioning. Human evidence from large populations offers critical insights to navigate and de-risk R&D: ensure target safety and efficacy at the earliest stages and align target biology with the right clinical phenotypes benefitting from target modulation.

September 17, 2024

10

min read

Why Pheiron and Why Now?

Drug development is broken: Over 90% of drug development programs entering clinical development fail, costing the industry an average of $6.16bn for a novel approved drug. The root of the problem? Insufficient evidence to anticipate clinical efficacy. We build Pheiron to change that - in silico and at scale.

February 16, 2024

8

min read

Align between targets, assets and populations.

Subscribe to our newsletter and stay tuned on Predictive Evidence in drug development.
PreferencesLegalPrivacy